Date:
Tue, March 27, 2007 11:27:06 PMFrom:
newsletter@newsone.mdlinx.com
Subject:
DrugLinx : Marketing/Media/ROI Newsletter 03/27/2007 10:10PM
|
When you registered with www.MDLinx.com, you subscribed to this newsletter. Please add this email address (newsletter@newstwo.mdlinx.com) to your address book to ensure safe delivery. |
![]() | Marketing/Media/ROI Daily Newsletter Tuesday, March, 27 2007 | |||
| ||||
| Home | News | CME | Conferences | Resource Center | Job Center | Help | ||||
|
![]() Sponsor
![]() Sponsor
![]() Sponsor
![]() Sponsor | |||||||
GE Healthcare became the world market share leader in the compact ultrasound industry in 2006, as cited in a recent industry report issued by Klein Biomedical Consultants, an internationally recognized source of ultrasound market and trends. GE was the market leader with a 43 percent share, according to the report...[more...] Corporate News Releases, 03/27/07 Free Full Text Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets Mylan Laboratories Inc. announced its latest first to market generic product with the launch of Ciprofloxacin Extended-release (ER) Tablets in 500mg and 1000mg strengths. Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for both strengths of Ciprofloxacin ER Tablets, March 22 and began shipping immediately that day. Ciprofloxacin ER is the latest Mylan generic product that leverages Mylan's expertise in extended release formulations...[more...] Corporate News Releases, 03/27/07 Free Full Text Victory Pharma, Inc. Sales Force Expansion Signifies Growth of Its US Commercial Operations Victory Pharma, Inc. a specialty pharmaceutical company with a portfolio of pain related products, announced that it has completed its sales force expansion. The sales force promotes the Company's unique and innovative line of prescription pain products including recently acquired marketing rights for NAPRELAN...[more...] Corporate News Releases, 03/27/07 Free Full Text Protox Outlines Milestones for 2007 Protox TM Therapeutics Inc. announced the company's key milestones for the coming year that will help position the company as a leader in targeted therapeutics for cancer and other proliferative diseases. They include the completion of a Phase I study in prostate cancer, the initiation of a Phase I study in benign prostatic hyperplasia and the initiation of a Phase IIb study in brain cancer...[more...] Protox Therapeutics , 03/27/07 Free Full Text AstraZeneca expects strong sales growth in China AstraZeneca expects sales in China to grow more than 20 pct annually in the 2007-2010 period, the Shanghai Daily reported, citing James Ward-Lilley, president of AstraZeneca China.To develop drugs for the Chinese market, AstraZeneca said that it had chosen Shanghai's Zhangjiang High-Tech Industrial Park as a base for its research and development effort, part of plans to invest up to 100 mln usd in R&D in China...[more...] PharmiWeb, 03/26/07 Free Full Text Pfizer Announces Launch of Generic Amlodipine Besylate Product by Greenstone In response to an announcement by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company's Greenstone subsidiary. Norvasc also will remain available to patients. Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six-month pediatric exclusivity period that expires in September, 2007...[more...] Corporate News Releases, 03/26/07 Free Full Text Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in Japan to Merck & Co., Inc. Cubist Pharmaceuticals, Inc. announced that it has entered into a license agreement with Merck & Co., Inc. for the development and commercialization of CUBICIN (daptomycin for injection) in Japan. Merck will develop and commercialize CUBICIN through its wholly-owned subsidiary, Banyu Pharmaceutical Co., Ltd. With this agreement in Japan, Cubist has secured an excellent partner for CUBICIN, its first-in-class lipopeptide antibiotic, and now has a full complement of partners ready to commercialize CUBICIN around the world. Cubist commercializes CUBICIN in the United States...[more...] Corporate News Releases, 03/23/07 Free Full Text Boston Scientific iLab(TM) System Hits Record Sales Boston Scientific Corporation announced that worldwide sales of its iLab(TM) Ultrasound Imaging (IVUS) System have passed the 300 unit mark in just nine months since launch of the system in May of 2006. This is double the number of sales realized by the Galaxy(2)(TM) Imaging System, the predecessor to the iLab System and represents a significant increase in market penetration for the company's IVUS technology...[more...] Corporate News Releases, 03/23/07 Free Full Text GSK Announces Nationwide Availability of Once-A-Day COREG CR(TM) for the Treatment of Three Key Cardiovascular Conditions GlaxoSmithKline announced that Coreg CR(TM) (carvedilol phosphate) extended- release capsules, a once-a-day beta-blocker, is now available at pharmacies nationwide. COREG CR is FDA-approved to treat three cardiovascular conditions: High blood pressure, also known as hypertension. A heart attack that has reduced how well the heart pumps (known medically as post-myocardial infarction left ventricular dysfunction). Mild to severe heart failure...[more...] Corporate News Releases, 03/23/07 Free Full Text Cambridge Heart Announces Co-Marketing Agreement with St. Jude Medical and a $12.5 Million Equity Investment Cambridge Heart, Inc., announced a three-year exclusive sales and marketing agreement with St. Jude Medical, Inc., under which St. Jude Medical will be responsible for marketing Cambridge Heart's HearTwave II Microvolt T-Wave Alternans System and sensors to cardiologists and electrophysiologists in North America. Cambridge Heart's sales force will continue to market the HearTwave II to internal medicine and primary care practices. Alternans testing is designed to allow physicians to identify patients who are at increased risk of Sudden Cardiac Death (SCD)...[more...] Corporate News Releases, 03/22/07 Free Full Text [view more articles]
| ||||||||
|
||||||||
| ||||||||
| When you signed up for MDLinx you requested this email be sent to you. To manage your newsletters and alert please login to your MDLinx account at:Login and click Manage Newsletters. If you do not wish to receive this newsletter, click here to ***: *** Me |
| ? 2007, MDLinx, Inc. |
| MDLinx considers the privacy of its users to be of utmost importance and works to protect it. MDLinx uses personal user information for internal purposes only. We will not sell or share your information with outsiders. For comprehensive information about the steps that MDLinx takes to respect your privacy please read our Privacy Policy: |
| This email has been sent by MDLinx, Inc. 1232 22nd Street NW Washington, DC 20037 Tel: +1.202.293.2288 Fax: +1.202.293.1690 |


Back to newsletter list

